Bausch Health Signs New Board Agreements

The latest announcement is out from Bausch Health Companies ( (TSE:BHC) ).

On May 20, 2025, Bausch Health Companies Inc. entered into letter agreements with Carl Icahn, John Paulson, and Sarah Kavanagh, who are overlapping directors on the boards of Bausch Health and Bausch + Lomb. These agreements stipulate that if any group engages in specified actions, they must resign from the boards. Additionally, the Icahn Group waived certain rights under a previous agreement. The agreements also ensure that, as long as no specified actions are taken, the company will support these groups’ nominees for board positions and allow them to join new board committees.

The most recent analyst rating on (TSE:BHC) stock is a Hold with a C$10.00 price target. To see the full list of analyst forecasts on Bausch Health Companies stock, see the TSE:BHC Stock Forecast page.

Spark’s Take on TSE:BHC Stock

According to Spark, TipRanks’ AI Analyst, TSE:BHC is a Neutral.

Bausch Health’s overall score reflects its solid revenue growth and cash flow generation capabilities, countered by high leverage and ongoing profitability issues. Technical indicators and valuation metrics are unfavorable, while recent earnings calls provide some optimism. Addressing financial stability and profitability concerns is crucial for long-term improvement.

To see Spark’s full report on TSE:BHC stock, click here.

More about Bausch Health Companies

Bausch Health Companies Inc. operates in the pharmaceutical industry, focusing on the development, manufacture, and marketing of a wide range of pharmaceutical products, primarily in the areas of eye health, gastroenterology, and dermatology.

Average Trading Volume: 388,264

Technical Sentiment Signal: Strong Sell

Current Market Cap: C$2.41B

For detailed information about BHC stock, go to TipRanks’ Stock Analysis page.